ClinicalTrials.gg
CompletedNCT06556966Updated May 29, 2025

A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects

A Phase 1 interventional study of LY03020 and Placebo in Schizophrenia and Alzheimer's Disease Psychosis, sponsored by Luye Pharma Group Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Luye Pharma Group Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Schizophrenia by Luye Pharma Group Ltd. — 3 open to participants now, 4 under way, none of them phase 3. Schizophrenia · Luye Pharma Group Ltd..

Enrollment
5th of 12
66 · median 44
Started
2024
the only one that year
Phase 1
11 of 12
2 open now
Registered
8th of 12
by date

Among the 12 studies in Schizophrenia by Luye Pharma Group Ltd., this one is the 5th largest by enrollment, is the only one that started in 2024, is one of 11 in phase 1, and was the 8th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 12 studies in Schizophrenia by Luye Pharma Group Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Schizophrenia by Luye Pharma Group Ltd., or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, ascending single oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects.

Read the detailed description

The study will set 2.5mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg and 100mg, a total of 8 dose groups. Qualified subjects were enrolled in site at D-1 ( 1 day before administration ) and randomized.The subjects should fast for at least 10 hours before medication administration, with no restrictions on water intake. The subjects will be required to orally take LY03020 or a placebo on an empty stomach upon waking on D1 (the day of medication administration). From D1 to D7, they will undergo safety assessments and PK biological sample collection.

03

Conditions studied

  • Schizophrenia
  • Alzheimer's Disease Psychosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects sign voluntarily.
  • Male or female aged 18 to 45 years.
  • Body weight ≥ 50.0 kg for male and ≥ 45.0 kg for female, and male or female greater than or equal to 18.5 but less than 26.0 kg/m2 of (BMI).

Exclusion criteria

Exclusion Criteria:

  • Subjects have any medical condition or chronic disease.
  • Subjects experienced a history of keratopathy, fundus disease, increased intraocular pressure,or angle-closure glaucoma.Subjects have a abnormal and clinically significant test for ophthalmic examination during screening.
  • Subjects with condition that may interfere with the drug absorption, distribution, metabolism and excretion significantly.
  • Subjects had a history of surgery within 3 months prior to administration, or had not recovered, or have a surgical plan during the study.
  • Subjects have any clinically significant abnormal vital signs, laboratory values, and ECGs.
  • Subjects have used any of nonprescription drugs within 7 days or prescription drugs within 28 days prior to administration.
  • Subjects have a history of allergic diseases, or allergic to any substance contained in the formulation
  • Subjects have a positive test for , -Ab, -Ab, or syphilis serum reaction.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    LY03020

    Subjects will take single-dose LY03020 on Day 1

    Drug: LY03020

  • Sham comparator
    Placebo

    Subjects will take single-dose Placebo on Day 1

    Drug: Placebo

Interventions

  • LY03020 for one single dose

    Also known as: LPM787000048 Maleate sustained-release tablet

  • DrugPlacebo

    Placebo for one single dose

    Also known as: Placebo of LPM787000048 Maleate sustained-release tablet

06

What researchers measure

Primary outcomes

  1. Frequency of adverse events (AEs)

    Percentage of adverse events

    Time frame: up to144 hours

Secondary outcomes

  1. Maximum observed concentration (Cmax) of LPM787000048 in plasma

    Subject blood samples will be collected at 17 time points and pharmacokinetic parameters will be calculated.

    Time frame: up to144 hours

  2. Time to maximum observed concentration (Tmax) of LPM787000048 in plasma

    Subject blood samples will be collected at 17 time points and pharmacokinetic parameters will be calculated.

    Time frame: up to144 hours

  3. Area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of LPM787000048 in plasma

    Subject blood samples will be collected at 17 time points and pharmacokinetic parameters will be calculated.

    Time frame: up to144 hours

  4. Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-t) of LPM787000048 in plasma

    Subject blood samples will be collected at 17 time points and pharmacokinetic parameters will be calculated.

    Time frame: up to144 hours

  5. Apparent terminal elimination half-life (t1/2) of LPM787000048 in plasma

    Subject blood samples will be collected at 17 time points and pharmacokinetic parameters will be calculated.

    Time frame: up to144 hours

  6. Apparent volume of distribution(Vz/F) of LPM787000048 in plasma

    Subject blood samples will be collected at 17 time points and pharmacokinetic parameters will be calculated.

    Time frame: up to144 hours

  7. Apparent total body clearance (CL/F) of LPM787000048 from plasma

    Subject blood samples will be collected at 17 time points and pharmacokinetic parameters will be calculated.

    Time frame: up to144 hours

Other outcomes

  1. Quantitatively determine the concentration of LPM787000048 and major metabolites (if applicable) in urine and calculate the cumulative excretion ratio in urine.

    One dose group will be selected for metabolite identification.

    Time frame: up to144 hours

07

Study locations

1 site
  • Beijing AnDing Hospital Capital Medical University
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Feb 2025, 5 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2024
First posted
Aug 16, 2024
StartActual
Aug 19, 2024
Primary completionActual
Feb 13, 2025
CompletionActual
Feb 13, 2025
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06556966
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Aug 19, 2024
Primary completion
Feb 13, 2025
Completion
Feb 13, 2025
Last update
May 29, 2025

Study contacts

Gang Wang
principal investigator · Beijing AnDing Hospital Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY03020

Start the discussion